Recurrent multiple myeloma
Clinical trials for Recurrent multiple myeloma explained in plain language.
Never miss a new study
Get alerted when new Recurrent multiple myeloma trials appear
Sign up with your email to follow new studies for Recurrent multiple myeloma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New Four-Drug cocktail aims to tackle tough myeloma
Disease control OngoingThis phase 2 trial tests a combination of four drugs—isatuximab, carfilzomib, pomalidomide, and dexamethasone—in 30 patients with multiple myeloma that has relapsed or become resistant to treatment. The goal is to see how many patients respond to this regimen. All participants ha…
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase 2 • Sponsor: University of Washington • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New targeted radiation therapy aims to improve stem cell transplants for tough myeloma
Disease control CancelledThis early-phase trial tests a new approach for high-risk multiple myeloma: a radioactive antibody that targets cancer cells, followed by a donor stem cell transplant. The antibody delivers radiation directly to myeloma cells, while chemotherapy and low-dose radiation help prepar…
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase 1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New combo therapy aims to outsmart resistant myeloma
Disease control PausedThis study tests whether adding the drug iberdomide to a standard treatment (belantamab mafodotin plus dexamethasone) is safe and works better for multiple myeloma that has relapsed or become resistant. About 88 participants will receive either the new combo or the standard combo…
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase 1/2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug cocktail shows promise for Tough-to-Treat myeloma
Disease control OngoingThis early-stage trial tests a new drug (CB-839 HCl) combined with two standard treatments for multiple myeloma that has returned or is not responding. The main goal is to find the safest dose and see how well the combination works. About 36 adults with relapsed or refractory mul…
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Gene-Edited immune cells take on Hard-to-Treat myeloma in early trial
Disease control PausedThis early-phase trial tests a new treatment for multiple myeloma that has come back or not responded to standard therapies. The treatment uses a patient's own immune cells (T cells) that are modified in the lab using CRISPR gene editing to recognize and attack cancer cells. Abou…
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase 1 • Sponsor: Thomas Martin, MD • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Multiple myeloma drug combo trial pulled before it even started
Disease control CancelledThis early-stage trial aimed to test the safety and best dose of an experimental oral drug called selvigaltin when added to standard treatments for multiple myeloma that had come back or stopped responding. The study was withdrawn before enrolling any participants, so no results …
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase 1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New hope for Hard-to-Treat myeloma: drug combo targets resistant cancer
Disease control OngoingThis early-phase trial tests a combination of three drugs (elotuzumab, mezigdomide, and dexamethasone) in 12 adults with multiple myeloma that has come back or stopped responding after prior treatments. The goal is to find the safest dose and see how well the body tolerates the r…
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase 1 • Sponsor: Abdullah Khan • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New hope for Hard-to-Treat myeloma: drug cocktail shows promise
Disease control OngoingThis study tests a combination of drugs (selinexor, pomalidomide, dexamethasone, and sometimes carfilzomib) in 39 adults with multiple myeloma that has returned or no longer responds to standard treatments. The goal is to find the best dose and see how well the combo controls the…
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase 1/2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Cancer treatment gets personal: MATCH trial tests Gene-Guided drugs
Knowledge-focused OngoingThis phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 30, 2026 00:00 UTC